Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 378

1.

Active Surveillance of Low-Risk Thyroid Cancer.

Zanocco KA, Hershman JM, Leung AM.

JAMA. 2019 May 28;321(20):2020-2021. doi: 10.1001/jama.2019.5350. No abstract available.

PMID:
31038662
2.

Response to Hennessey re: "Concurrent Milk Ingestion Decreases Absorption of Levothyroxine".

Chon DA, Reisman T, Weinreb JE, Hershman JM, Leung AM.

Thyroid. 2018 Aug;28(8):1075. doi: 10.1089/thy.2018.0262. Epub 2018 Jul 17. No abstract available.

PMID:
29848217
3.

Concurrent Milk Ingestion Decreases Absorption of Levothyroxine.

Chon DA, Reisman T, Weinreb JE, Hershman JM, Leung AM.

Thyroid. 2018 Apr;28(4):454-457. doi: 10.1089/thy.2017.0428. Epub 2018 Mar 28.

4.

Direct quantification of gamma H2AX by cell-based high throughput screening for evaluation of genotoxicity of pesticides in a human thyroid cell lines.

Hershman JM, France B, Hon K, Damoiseaux R.

Environ Mol Mutagen. 2017 Aug;58(7):522-528. doi: 10.1002/em.22103. Epub 2017 Jun 22.

5.

Pathogenesis of Hyperthyroidism.

Singh I, Hershman JM.

Compr Physiol. 2016 Dec 6;7(1):67-79. doi: 10.1002/cphy.c160001. Review.

PMID:
28134999
6.

HIGH PREVALENCE OF AGENT ORANGE EXPOSURE AMONG THYROID CANCER PATIENTS IN THE NATIONAL VA HEALTHCARE SYSTEM.

Le KT, Sawicki MP, Wang MB, Hershman JM, Leung AM.

Endocr Pract. 2016 Jun;22(6):699-702. doi: 10.4158/EP151108.OR. Epub 2016 Jan 27.

PMID:
27176142
7.

Lozenge-Induced Hypermineralcorticoid State--A Unique Case of Licorice Lozenges Resulting in Hypertension and Hypokalemia.

Dai DW, Singh I, Hershman JM.

J Clin Hypertens (Greenwich). 2016 Feb;18(2):159-60. doi: 10.1111/jch.12633. Epub 2015 Jul 25. No abstract available.

8.

Thyroid Nodules and Cancer in the Elderly.

Lechner MG, Hershman JM.

In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, Hershman JM, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Perreault L, Purnell J, Rebar R, Singer F, Trence DL, Vinik A, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.
2018 Dec 3.

9.

Thyrotoxicosis of Pregnancy.

Labadzhyan A, Brent GA, Hershman JM, Leung AM.

J Clin Transl Endocrinol. 2014 Dec 1;1(4):140-144.

10.

Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules.

Beaudenon-Huibregtse S, Alexander EK, Guttler RB, Hershman JM, Babu V, Blevins TC, Moore P, Andruss B, Labourier E.

Thyroid. 2014 Oct;24(10):1479-87. doi: 10.1089/thy.2013.0640. Epub 2014 Jun 18.

PMID:
24811481
11.

Thyroid hormone inactivation in gastrointestinal stromal tumors.

Maynard MA, Marino-Enriquez A, Fletcher JA, Dorfman DM, Raut CP, Yassa L, Guo C, Wang Y, Dorfman C, Feldman HA, Frates MC, Song H, Jugo RH, Taguchi T, Hershman JM, Larsen PR, Huang SA.

N Engl J Med. 2014 Apr 3;370(14):1327-34. doi: 10.1056/NEJMoa1308893.

12.

Sunitinib does not block thyroid peroxidase in patients.

Liwanpo L, Ro C, Haq S, Hershman JM.

Thyroid. 2014 Aug;24(8):1325-6. doi: 10.1089/thy.2014.0006. Epub 2014 Jun 25. No abstract available.

PMID:
24521256
13.

Clinical Review: Hashimoto's thyroiditis and papillary thyroid carcinoma: is there a correlation?

Jankovic B, Le KT, Hershman JM.

J Clin Endocrinol Metab. 2013 Feb;98(2):474-82. doi: 10.1210/jc.2012-2978. Epub 2013 Jan 4. Review.

PMID:
23293329
14.

Medullary thyroid cancer--current treatment strategy, novel therapies and perspectives for the future.

Sugawara M, Ly T, Hershman JM.

Horm Cancer. 2012 Dec;3(5-6):218-26. doi: 10.1007/s12672-012-0119-5. Epub 2012 Aug 4. Review.

PMID:
23011723
15.

Cyclic AMP-response element modulator inhibits the promoter activity of the sodium iodide symporter gene in thyroid cancer cells.

Passon N, Puppin C, Lavarone E, Bregant E, Franzoni A, Hershman JM, Fenton MS, D'Agostino M, Durante C, Russo D, Filetti S, Damante G.

Thyroid. 2012 May;22(5):487-93. doi: 10.1089/thy.2011.0360. Epub 2012 Apr 17.

PMID:
22510021
16.

Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport.

Braun D, Kim TD, le Coutre P, Köhrle J, Hershman JM, Schweizer U.

J Clin Endocrinol Metab. 2012 Jan;97(1):E100-5. doi: 10.1210/jc.2011-1837. Epub 2011 Oct 26.

PMID:
22031512
17.

Update in thyroidology 2010.

Hershman JM, Cheng SY, Gianoukakis AG.

J Clin Endocrinol Metab. 2011 Jan;96(1):9-14. doi: 10.1210/jc.2010-2350.

PMID:
21209040
18.

Prevention of DNA double-strand breaks induced by radioiodide-(131)I in FRTL-5 thyroid cells.

Hershman JM, Okunyan A, Rivina Y, Cannon S, Hogen V.

Endocrinology. 2011 Mar;152(3):1130-5. doi: 10.1210/en.2010-1163. Epub 2010 Dec 29.

19.

Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer.

Fenton MS, Marion KM, Salem AK, Hogen R, Naeim F, Hershman JM.

Thyroid. 2010 Sep;20(9):965-74. doi: 10.1089/thy.2010.0008.

PMID:
20629553
20.

Stability of recombinant human thyrotropin potency based on bioassay in FRTL-5 cells.

Lin R, Hogen V, Cannon S, Marion KM, Fenton MS, Hershman JM.

Thyroid. 2010 Oct;20(10):1139-43. doi: 10.1089/thy.2009.0408.

PMID:
20615135
21.

How does sunitinib cause hypothyroidism?

Hershman JM, Liwanpo L.

Thyroid. 2010 Mar;20(3):243-4. doi: 10.1089/thy.2010.1620. No abstract available.

PMID:
20187779
22.

Conditions and drugs interfering with thyroxine absorption.

Liwanpo L, Hershman JM.

Best Pract Res Clin Endocrinol Metab. 2009 Dec;23(6):781-92. doi: 10.1016/j.beem.2009.06.006. Review.

PMID:
19942153
23.

Novel treatment of medullary thyroid cancer.

Sugawara M, Geffner DL, Martinez D, Hershman JM.

Curr Opin Endocrinol Diabetes Obes. 2009 Oct;16(5):367-72. doi: 10.1097/MED.0b013e3283304f0c. Review.

PMID:
19633548
24.

Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase.

Tomoda C, Moatamed F, Naeim F, Hershman JM, Sugawara M.

Exp Biol Med (Maywood). 2008 Nov;233(11):1433-40. doi: 10.3181/0804-RM-127. Epub 2008 Sep 12.

PMID:
18791128
25.

The role of human chorionic gonadotropin as a thyroid stimulator in normal pregnancy.

Hershman JM.

J Clin Endocrinol Metab. 2008 Sep;93(9):3305-6. doi: 10.1210/jc.2008-1461. No abstract available.

PMID:
18772462
26.

Effect of sunitinib on growth and function of FRTL-5 thyroid cells.

Salem AK, Fenton MS, Marion KM, Hershman JM.

Thyroid. 2008 Jun;18(6):631-5. doi: 10.1089/thy.2007.0336.

PMID:
18578612
27.

Carbothermal synthesis of carbon-supported nanoscale zero-valent iron particles for the remediation of hexavalent chromium.

Hoch LB, Mack EJ, Hydutsky BW, Hershman JM, Skluzacek JM, Mallouk TE.

Environ Sci Technol. 2008 Apr 1;42(7):2600-5.

PMID:
18505003
28.

Expression of hepatocyte nuclear factor-1alpha mRNA in human anaplastic thyroid cancer cell lines and tumors.

Xu J, Filetti S, Hershman JM.

Thyroid. 2008 May;18(5):533-9. doi: 10.1089/thy.2007.0312.

PMID:
18399756
29.

Cinacalcet for the treatment of primary hyperparathyroidism.

Sajid-Crockett S, Singer FR, Hershman JM.

Metabolism. 2008 Apr;57(4):517-21. doi: 10.1016/j.metabol.2007.11.014.

PMID:
18328354
30.

Thyroid-stimulating hormone increases active transport of perchlorate into thyroid cells.

Tran N, Valentín-Blasini L, Blount BC, McCuistion CG, Fenton MS, Gin E, Salem A, Hershman JM.

Am J Physiol Endocrinol Metab. 2008 Apr;294(4):E802-6. doi: 10.1152/ajpendo.00013.2008. Epub 2008 Feb 26.

31.

Identification of cyclic adenosine 3',5'-monophosphate response element modulator as an activator of the human sodium/iodide symporter upstream enhancer.

Fenton MS, Marion KM, Hershman JM.

Endocrinology. 2008 May;149(5):2592-606. doi: 10.1210/en.2007-1390. Epub 2008 Jan 17.

32.

Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation.

Batcher EL, Tang XC, Singh BN, Singh SN, Reda DJ, Hershman JM; SAFE-T Investigators.

Am J Med. 2007 Oct;120(10):880-5.

PMID:
17904459
33.

Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity.

Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M, Hershman JM.

Thyroid. 2007 Apr;17(4):351-5.

PMID:
17465866
34.

RET/papillary thyroid carcinoma oncogenic signaling through the Rap1 small GTPase.

De Falco V, Castellone MD, De Vita G, Cirafici AM, Hershman JM, Guerrero C, Fusco A, Melillo RM, Santoro M.

Cancer Res. 2007 Jan 1;67(1):381-90.

35.

Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo.

Luong QT, O'Kelly J, Braunstein GD, Hershman JM, Koeffler HP.

Clin Cancer Res. 2006 Sep 15;12(18):5570-7.

37.

Iodide sensitizes genetically modified non-small cell lung cancer cells to ionizing radiation.

Zhang L, Sharma S, Hershman JM, Brent GA, Dubinett SM, Huang M.

Cancer Gene Ther. 2006 Jan 1;13(1):74-81.

PMID:
16052231
38.

Anaplastic thyroid carcinoma with thyrotoxicosis and hypoparathyroidism.

Heymann RS, Brent GA, Hershman JM.

Endocr Pract. 2005 Jul-Aug;11(4):281-4.

PMID:
16006301
39.

Perchlorate and thyroid function: what are the environmental issues?

Hershman JM.

Thyroid. 2005 May;15(5):427-31. Review.

PMID:
15929663
40.

Partial withdrawal of levothyroxine to stimulate serum thyroglobulin for thyroid cancer monitoring.

Soroushyari A, Do D, Langton J, Hershman JM.

Thyroid. 2004 Dec;14(12):1105-7. No abstract available.

PMID:
15666427
41.

Activation of nicotinamide N-methyltransferase gene promoter by hepatocyte nuclear factor-1beta in human papillary thyroid cancer cells.

Xu J, Capezzone M, Xu X, Hershman JM.

Mol Endocrinol. 2005 Feb;19(2):527-39. Epub 2004 Oct 14.

PMID:
15486044
42.
43.

Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells.

Vitagliano D, Carlomagno F, Motti ML, Viglietto G, Nikiforov YE, Nikiforova MN, Hershman JM, Ryan AJ, Fusco A, Melillo RM, Santoro M.

Cancer Res. 2004 Jun 1;64(11):3823-9.

44.

Physiological and pathological aspects of the effect of human chorionic gonadotropin on the thyroid.

Hershman JM.

Best Pract Res Clin Endocrinol Metab. 2004 Jun;18(2):249-65. Review.

PMID:
15157839
45.

Subclinical thyroid disease: scientific review and guidelines for diagnosis and management.

Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ.

JAMA. 2004 Jan 14;291(2):228-38. Review.

PMID:
14722150
46.

Bisphosphonate therapy in primary hyperparathyroidism.

Hershman JM, Hassani S, Braunstein GD, Geola F, Brickman A, Seibel MJ.

J Bone Miner Res. 2003 Oct;18(10):1889; author reply 1890. No abstract available.

47.

Enhanced expression of nicotinamide N-methyltransferase in human papillary thyroid carcinoma cells.

Xu J, Moatamed F, Caldwell JS, Walker JR, Kraiem Z, Taki K, Brent GA, Hershman JM.

J Clin Endocrinol Metab. 2003 Oct;88(10):4990-6.

PMID:
14557485
48.

Nonradioactive iodide effectively induces apoptosis in genetically modified lung cancer cells.

Zhang L, Sharma S, Zhu LX, Kogai T, Hershman JM, Brent GA, Dubinett SM, Huang M.

Cancer Res. 2003 Aug 15;63(16):5065-72.

50.

Lithium-associated thyroiditis.

Dang AH, Hershman JM.

Endocr Pract. 2002 May-Jun;8(3):232-6. Review.

PMID:
12113638

Supplemental Content

Loading ...
Support Center